Project Title: PAtient-derived Lung cancer Models Study (PALMS)
Project Duration: 2005-Present
MOHCCN Consortium: Princess Margaret Cancer Consortium
Investigators: Geoffrey Liu, Ming-Sound Tsao
The PALMS cohort includes lung cancer patients whose tumour (early-stage resectable or metastatic) have been used to establish patient-derived xenograft (PDX) models and/or organoid cell lines. The ability for the patient tumour to establish PDX is strongly correlated with aggressive clinical outcome. Therefore, once molecularly characterized, the PDXs represent excellent models to study molecular features that determine poor clinical outcome (prognosis), tumour heterogeneity, biomarkers of targeted or immunotherapy drug sensitivity, and mechanisms of drug resistance. The goals include using whole genome and transcriptomic data to understand:
PALMS is an initiative to use deep genomic and transcriptomic sequencing, drug response data and patient-derived models to improve predictive precision medicine in lung cancer.